30901590), and

Doctoral Fund of Shandong Province to Hui Zhang (NO.BS2009YY039). References 1. Seibaek L, Petersen LK, Blaakaer J, Hounsgaard L: Symptom interpretation and health care seeking in ovarian cancer. BMC Womens Health 2011, 11:31.PubMedCrossRef 2. Salzman J, Marinelli RJ, Wang PL, Green AE, Nielsen JS, Nelson BH, et al.: GSK1904529A manufacturer ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma. PLoS Biol 2011, 9:e1001156.PubMedCrossRef 3. Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502–516.PubMedCrossRef 4. Huber BE, Richards CA, Austin EA: Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann N Y Acad Sci 1994, 716:104–14. discussion 40–43PubMedCrossRef 5. Marais

R, Spooner RA, Light Y, Martin J, Springer CJ: Gene-directed Selleck MCC-950 enzyme prodrug therapy with a mustard prodrug/carboxypeptidase selleck inhibitor G2 combination. Cancer Res 1996, 56:4735–4742.PubMed 6. Lv SQ, Zhang KB, Zhang EE, Gao FY, Yin CL, Huang CJ, et al.: Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Med Sci Monit 2009, 15:BR13-BR20.PubMed 7. Finocchiaro LM, Riveros MD, Glikin GC: Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse. Vet Rec 2009, 164:278–279.PubMedCrossRef 8. Xu B, Liu ZZ, Zhang J, Zong XL, Cai JL: Effects of recombinant adenovirus-mediated double suicide genes on implanted human keloid:

experiment with athymic mice. Zhonghua yi xue za zhi 2008, 88:3428–3431.PubMed 9. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al.: Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus crotamiton thymidine kinase/ganciclovir system in vitro. Gene Ther 1996, 3:85–92.PubMed 10. Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, et al.: A “distant” bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997, 8:1807–1814.PubMedCrossRef 11. Yoshimura T, Leonard EJ: Human monocyte chemoattractant protein-1: structure and function. Cytokines 1992, 4:131–152.PubMed 12. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994, 91:3652–3656.PubMedCrossRef 13. Tsuchiyama T, Nakamoto Y, Sakai Y, Mukaida N, Kaneko S: Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Cancer Sci 2008, 99:2075–2082.PubMedCrossRef 14. Iida N, Nakamoto Y, Baba T, Kakinoki K, Li YY, Wu Y, et al.: Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. J Leukoc Biol 2008, 84:1001–1010.PubMedCrossRef 15.